tbuckley/cabot-search huggingface dataset:
Exploration of the Relationship Between Household Food Insecurity and Diabetes in Canada
Authors: Enza Gucciardi, Janet A. Vogt, Margaret DeMelo, Donna E. Stewart
Journal: Diabetes Care (2009)

OBJECTIVE To determine the household food insecurity (HFI) prevalence in Canadians with diabetes and its relationship with diabetes management, self-care practices, and health status. RESEARCH DESIGN AND METHODS We analyzed data from Canadians with diabetes aged ≥12 years (n = 6,237) from cycle 3.1 of the Canadian Community Health Survey, a population-based cross-sectional survey conducted in 2005. The HFI prevalence in Canadians with diabetes was compared with that in those without diabetes. The relationships between HFI and management services, self-care practices, and health status were examined for Ontarians with diabetes (n = 2,523). RESULTS HFI was more prevalent among individuals with diabetes (9.3% [8.2–10.4]) than among those without diabetes (6.8% [6.5–7.0]) and was not associated with diabetes management services but was associated with physical inactivity (odds ratio 1.54 [95% CI 1.10–2.17]), lower fruit and vegetable consumption (0.52 [0.33–0.81]), current smoking (1.71 [1.09–2.69]), unmet health care needs (2.71 [1.74–4.23]), having been an overnight patient (2.08 [1.43–3.04]), having a mood disorder (2.18 [1.54–3.08]), having effects from a stroke (2.39 [1.32–4.32]), lower satisfaction with life (0.28 [0.18–0.43]), self-rated general (0.37 [0.21–0.66]) and mental (0.17 [0.10–0.29]) health, and higher self-perceived stress (2.04 [1.30–3.20]). The odds of HFI were higher for an individual in whom diabetes was diagnosed at age &amp;lt;40 years (3.08 [1.96–4.84]). CONCLUSIONS HFI prevalence is higher among Canadians with diabetes and is associated with an increased likelihood of unhealthy behaviors, psychological distress, and poorer physical health.
Mother Protecting Her Child
Authors: M. Therese Southgate
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improved Diagnosis of Unilateral Renal Artery Lesions After Captopril Administration
Authors: Marc Thibonnier
Journal: JAMA (1984)

Captopril was administered (1 mg/kg of body weight) to 37 unselected hypertensive patients undergoing bilateral renal vein catheterization to determine its safety and efficacy in diagnosing hypertension related to unilateral renal artery lesions. In the 18 patients who had a unilateral renal artery lesion demonstrated by angiography, the ratio of plasma renin activity of the involved to uninvolved renal vein rose significantly after administration of captopril, whether or not patients were taking antihypertensive medication. This postcaptopril ratio differentiated cases of unilateral lesions from cases of bilateral lesions or absence of lesions without any overlap. The test was well tolerated despite occasional large drops in blood pressure. These data show that converting enzyme inhibition increases the diagnostic accuracy of renal vein catheterization by increasing the difference between the amount of plasma renin secreted by the two kidneys in cases of unilateral renal artery lesions. (<i>JAMA</i>1984;251:56-60)
Pancreatic Tumor Genes
Authors: Tracy Hampton
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Moderate Exercise for Improvement in 6-Minute Walk Test Performance in Stable Coronary Heart Disease—Reply
Authors: Alexis L. Beatty, Nelson B. Schiller, Mary A. Whooley
Journal: JAMA Internal Medicine (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Interleukin-6 and C-Reactive Protein in Metastatic Renal Cell Carcinoma
Authors: Ozden Altundag, Kadri Altundag, Esra Gunduz
Journal: Journal of Clinical Oncology (2005)

THE EDITOR: We read with great interest the study by Negrier et al, 1 which stated that circulating interleukin-6 (IL-6) level appears to beanimportant independent prognostic factor in patients with metastatic renal cell carcinoma (RCC).IL-6 plays a major role in inflammatory processes.It modulates the transcription of several liver-specific genes during acute inflammatory states, particularly C-reactive protein (CRP).Metastatic RCC is also associated with a high incidence of paraneoplastic syndrome, a condition characterized by fever and elevated levels of acute-phase markers (eg, CRP), as well as by a decrease in serum albumin, thrombocytosis, and anemia, all of which appear to be due to abnormal cytokine production (eg, IL-6) or immunogenic mechanisms.Blay et al 2 found that serum levels of IL-6 in RCC patients with paraneoplastic fever and weight loss were higher than those in RCC patients without paraneoplastic symptoms, thus suggesting a role for IL-6 in this syndrome.Three patients with paraneoplastic syndrome entering the study by Blay et al were treated with a monoclonal antibody to IL-6 therapy, and all showed reduced levels of CRP, haptoglobin, and serum alkaline phosphatases over21 days of treatment.In light of the above information, prognostic significance of CRP, as well as the other cytokines, in metastatic RCC must be determined.Moreover, CRP measurement is also more cost effective than IL-6 measurement in routine practice.
A familial syndromic association between cutaneous malignant melanoma and neural system tumours: reply from authors
Authors: K. NIELSEN, C. INGVAR, A. MASBaCK, J. WESTERDAHL, A. BORG, T. SANDBERG, N. JONSSON, J. NAGEL, H. OLSSON
Journal: British Journal of Dermatology (2004)

Journal Article A familial syndromic association between cutaneous malignant melanoma and neural system tumours: reply from authors Get access K. NIELSEN, K. NIELSEN Department of Dermatology, Surgery Search for other works by this author on: Oxford Academic Google Scholar C. INGVAR, C. INGVAR Department of Dermatology, Surgery Search for other works by this author on: Oxford Academic Google Scholar A. MÅSBäCK, A. MÅSBäCK †Pathology Search for other works by this author on: Oxford Academic Google Scholar J. WESTERDAHL, J. WESTERDAHL Department of Dermatology, Surgery Search for other works by this author on: Oxford Academic Google Scholar Å. BORG, Å. BORG ‡Oncology Search for other works by this author on: Oxford Academic Google Scholar T. SANDBERG, T. SANDBERG ‡Oncology Search for other works by this author on: Oxford Academic Google Scholar N. JONSSON, N. JONSSON †Pathology Search for other works by this author on: Oxford Academic Google Scholar J. NAGEL, J. NAGEL ‡Oncology Search for other works by this author on: Oxford Academic Google Scholar H. OLSSON H. OLSSON †Pathology§Cancer Epidemiology, University Hospital, S‐221 85 Lund, Sweden E‐mail: kari.nielsen@telia.com Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 151, Issue 6, 1 December 2004, Page 1279, https://doi.org/10.1111/j.1365-2133.2004.06291.x Published: 01 December 2004
Metal stent migration after chemotherapy
Authors: B. Mangiavillano, E. Masci, P. Testoni
Journal: Endoscopy (2007)

Self-expandable metal stents (SEMS) have been widely used to relieve malignant obstruction of the upper and lower gastrointestinal tract [1] [2]. There is now a considerable body of experience reported in the literature on colonic stent insertion for the treatment of malignant disease, both as a palliative measure and as a ”bridge to surgery“ [3]. There are several potential complications associated with stent insertion, however. A pooled analysis of the use of SEMS for the palliation of malignant colorectal obstruction showed that colonic stent migration occurred in 11.8 % of cases [4], though SEMS are only very rarely expelled right through the anal sphincter. We report a case of SEMS migration following chemotherapy, with subsequent expulsion of the SEMS across the anal sphincter and manual removal.
Histochemistry and Biochemistry of the Diseases of the Central and Pheripheral Nervous System. Thema I, vol. I. IV International Congress of Neuropathology, September 4-8, 1961
Authors: George B. Udvarhelyi
Journal: JAMA (1962)

"Approximately one-third of the communications given at the Fourth International Congress of Neuropathology have dealt with histochemistry or have identified histochemical techniques." This statement, with corresponding warnings about misuse and misinterpretations of these new techniques, was made by the Chairmen of the Official Themes, Pearse, Shimizu, and Wolman, in the summary of the proceedings at the end of this magnificently presented volume. Indeed, the extraordinarily rapid progress of histochemical and biochemical approaches to the problems concerning the central nervous system made it necessary for the Editorial Committee to limit the length of each communication to 5 to 8 pages and 2 to 3 illustrations. However, this synoptic panorama of new fields in the study of structure and function of the central nervous system gives insight into new perspectives and possibilities for future research. The volume opens with reproductions of the various opening speeches of the Congress. President Haymaker, in his
Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease
Authors: T Suou, S Yamada, K Hosho, N Yoshikawa, H Kawasaki
Journal: Hepatology (1996)

We evaluated the mechanism of increased serum concentrations of the 7S fragment of the N-terminal domain of type IV collagen (7S collagen) in chronic liver disease. We measured the concentrations of hepatic-free and deposited 7S collagens after extraction with Tris-HCl buffer and bacterial collagenase, then compared them with the serum levels in 8 normal controls and 48 patients with chronic liver disease. The hepatic 7S collagen levels extracted with Tris-HCl buffer and collagenase accounted for 7% and 93%, respectively, of the total 7S collagen levels in normal controls. Both hepatic 7S collagen levels as well as serum levels increased in accordance with the progress of liver disease. Serum levels of 7S collagen showed a closer correlation with the hepatic 7S collagen levels extracted with Tris-HCl buffer (r = .822), compared with those extracted with collagenase (r = .382). On the other hand, the histological degrees of liver fibrosis were highly correlated with the hepatic collagenase-extracted 7S collagen levels (r = .822), compared with serum and the hepatic Tris-HCl buffer-extracted levels (r = .478 and r = .537, respectively). Although there was no difference in serum and hepatic 7S collagen levels between B and C viral patients, the serum and hepatic Tris-HCl buffer-extracted 7S collagen levels were higher in patients with alcoholic cirrhosis than patients with viral cirrhosis. However, the hepatic collagenase-extracted levels were similar in both groups. Gel filtration demonstrated that the serum and hepatic Tris-HCl buffer-extracted 7S collagens were mainly eluted in the macromolecular 7S collagen-reactive fraction in cirrhosis, whereas the hepatic collagenase-extracted 7S collagen was eluted in the authentic 7S collagen-reactive fraction. The results suggest that serum 7S collagen levels are not a particularly reliable measure of hepatic fibrosis but reflect the enhanced metabolism, especially synthesis of type IV collagen in the liver.
593. Progress towards DNA-Based and siRNA Therapeutics
Authors: Michael R. Jorgensen, Michael Keller, Eric Perouzel, Andrew D. Miller
Journal: Molecular Therapy (2005)

The development of clinically viable, synthetic non-viral delivery systems for targeted delivery of DNA to cells has been a major preoccupation of many laboratories world-wide. In our hands, we have been attempting the rational design and development of self-assembly, synthetic complexes involving cationic liposomes (L) and nucleic acids such as plasmid DNA (pDNA, D), for this purpose. However, even after our development of the non-viral vector platform system known as liposome:mu:DNA (LMD), significant problems appear to remain before clinically viable DNA delivery may be realized. By contrast, we have found that our cationic liposome/lipid-based vector systems appear to be much better suited for the delivery of siRNA to cells (siFection). Drawing upon our experiences with pDNA delivery to cells (transfection), IC-Vec has developed a proprietary, self-assembly ABCD nanoparticle technology (CONZENTRx|[trade]|) that is well adapted for siFection in vitro and in vivo. Formulations are reproducible and scalable in all cases. For in vitro use, we have developed a potent new cationic liposome system (siFECTamine|[reg]|) that combines with siRNA (siR) to give LsiR particles (AB system) for siFection at very low siRNA doses with negligible toxicity. This simple AB system may then be upgraded for in vivo applications by using a highly selective and efficient proprietary bioconjugation chemistry to introduce chemical components for biological stability (C layer) and/or for biological targeting (D layer). The resulting nanoparticles (siFECTplus|[trade]|; ABC, ABD or ABCD systems) are closely size controlled and proof of concept studies demonstrate that purpose-designed siFECTplus|[trade]| nanoparticles (70nm) are able to deliver siRNA to murine liver in vivo causing substantial and specific protein down regulation with minimal detectable toxicity. CONZENTRx|[trade]| formulations make use of tool-kits of chemical components ensuring that siFECTplus|[trade]| nanoparticles can be tailor-made for individual siRNA delivery requirements. In collaboration with our strategic alliance partner, RNAi Co., the future for siRNA therapeutics looks promising. Data from further proof of concept studies in animal models will be presented demonstrating siRNA therapeutic approaches for the treatment of hepatitis and other diseases, assisted by siFECTplus|[trade]| nanoparticle delivery.
Screening for HCV Infection in Jails
Authors: Anne C. Spaulding, David L. Thomas
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of chronic epilepsy
Authors: F. J. Rugg-Gunn, J. W. Sander
Journal: BMJ (2012)

#### Summary points

Epilepsy can be defined pragmatically as the occurrence of at least two unprovoked epileptic seizures. It is the commonest serious neurological condition in adults, directly affecting over 400 000 people in the United Kingdom and up to 60 million people worldwide.1 Prevalence of epilepsy in developed countries is about 0.5%; however, the lifetime risk of a person having a non-febrile epileptic seizure is much higher at 2-5%, implying, for most patients, remittance of the condition or premature death.

Risk of a second seizure occurring within two years of the first event is about 50%. Early treatment with antiepileptic drugs after the first seizure does not affect the long term prognosis, with 75-80% achieving remission at five years, irrespective of whether treatment began after the first seizure or only after a recurrence.2 3 Treatment is therefore typically reserved for people who have had at least two seizures; the risk of a third seizure in these patients is over 70%. A tailored approach to treatment should always be adopted, since there could be circumstances in which …
Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease
Authors: B. Peter Sawaya, Rezkalla Butros, Shehzab Naqvi, Zhaopo Geng, Hanna Mawad, Robert Friedler, Paolo Fanti, Marie-Claude Monier-Faugere, Hartmut H. Malluche
Journal: Kidney International (2003)
Phenotypic modulation of smooth muscle cells in lymphoedema
Authors: F. Ogata, K. Fujiu, I. Koshima, R. Nagai, I. Manabe
Journal: British Journal of Dermatology (2014)

Background Lymphoedema is a debilitating progressive condition that is frequently observed following cancer surgery and severely restricts quality of life. Although it is known that lymphatic dysfunction and obstruction underlie lymphoedema, the pathogenic mechanism is poorly understood. Smooth muscle cells (SMCs) play pivotal roles in the pathogenesis of various vascular diseases, including atherosclerosis. Objectives We analysed SMCs in lymphatic vessels from the lymphoedematous legs of 29 patients. Methods Expression of smooth muscle α-actin (SMαA) and smooth muscle myosin heavy chain (SM-MHC) isoforms SM1 and SM2 was investigated using immunohistochemistry. Results Compared with normal lymphatic vessels, all affected lymphatic vessels in chronic lymphoedema showed marked wall thickening. In addition to increases in the numbers of rows of SMαA+ SM1+ SMCs in the tunica media, SMCs were also observed in the subendothelial region (tunica intima). While most intimal and medial cells were positive for SMαA and SM1, staining for SM1 and particularly SM2, a marker of mature SMCs, progressively declined in lymphatic vessels in increasingly severe lymphoedema lesions. Consequently, the SM1+ and SM2+ cell fractions were significantly reduced in the tunica media and intima of lymphatic vessels. Conclusions These observations indicate that the lymphatic tunica media and tunica intima consist mainly of phenotypically modulated SMCs, and that SMCs play a key role in the development of lymphoedema.
Wilson’s Disease: Indications for Liver Transplants
Authors: Irmin Sternlieb
Journal: Hepatology (1984)

The clinical course of certain patients with Wilson's disease resembles that of patients with viral or drug-induced fulminant hepatitis lasting only few weeks from recognition of symptoms to severe hepatic insufficiency and death. The disease is complicated by hemolysis and is characterized by hypercupremia. Routine laboratory findings may underestimate the severity of the disease. These patients, as well as patients with decompensated Wilsonian cirrhosis who are not responding to therapy, should be considered as candidates for liver transplants.
Hemolytic Disease of the Newborn: Lowest Achievable Incidence Rates
Authors: Paul A. Hensleigh
Journal: JAMA (1991)

<h3>To the Editor.</h3> —Chavez et al<sup>1</sup>found the estimated incidence rate of Rh hemolytic disease of the newborn to be 10.6 per 10 000 total births. They also calculate the minimum achievable incidence rates of Rh disease in the United States to be 3.1 per 10 000 total births. Based on these estimates we appear to be far from the achievable minimum, presumably due to failures to use antenatal and postpartum Rh(D) immune globulin (RhIg). An alternate explanation is that the failure rate of combined antenatal and postpartum use of RhIg that the authors took from the data and method of Bowman and Pollock may be incorrect. The studies from which these data were derived used "controls" that were neither contemporary nor matched. Other studies have found failure rates of antenatal and postpartum RhIg to be as high as 0.4% for primiparous patients and 0.85% for multiparous patients.<sup>2</sup>